[Use of a new antibiotic in Norway].
Brubakk
Oddbjørn
O
Infeksjonsmedisinsk avdeling Medisinsk divisjon Ullevål universitetssykehus 0407 Oslo. oddb@uus.no.
Bjørneklett
Arvid
A
Sjursen
Haakon
H
Viggen
Bjørg
B
D000081:Acetamides / Q000008:administration & dosage* / Q000009:adverse effects; D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D004342:Drug Hypersensitivity; D016903:Drug Monitoring; D024901:Drug Resistance, Multiple, Bacterial; D004363:Drug Utilization; D005260:Female; D006801:Humans; D000069349:Linezolid; D008297:Male; D009664:Norway; D023303:Oxazolidinones / Q000008:administration & dosage* / Q000009:adverse effects; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy
D000081:Acetamides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid